SuperworthuniQure price to free cash flow QURE
Market value divided by free cash flow over the last twelve months, since 2021.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 4.2×
- Aug 2022
- Peer median
- 8.9×
uniQure's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.
It was last meaningful in Aug 2022, at 4.2×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2022 | 4.2× | 2.2× | 4.2× |
| 2021 | 3.4× | 3.4× | 5.8× |
Against its peers
Companies in Drug Manufacturers - General nearest uniQure's size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| QUREuniQure | n/m |
| PAHCPhibro Animal Health | 160× |
| ANABAnaptysbio | n/m |
| PCRXPacira BioSciences | 8.1× |
| ANIPANI Pharmaceuticals | 9.6× |
| OMEROmeros | n/m |
| HRMYHarmony Biosciences | n/m |
| AMPHAmphastar Pharmaceuticals | 7.0× |
| PBHPrestige Consumer Healthcare | 9.6× |
| NRIXNurix Therapeutics | 7.5× |
| ABUSArbutus Biopharma | n/m |
| Peer median | 8.9× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on uniQure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.